2025 Conference Will Welcome Health & Wellness Thought Leaders Including Dr. Gabrielle Lyon, Teal Swan, Hal Elrod & Dr. Alberto Villoldo, May 28-30
AUSTIN, Texas, June 4, 2024 /PRNewswire/ — The Biohacking Conference, the largest of its kind in the world, will be heading to Austin, TX from May 28-30, 2025, taking over the Fairmont Hotel for an epic 3-day event, led by the “Father of Biohacking” Dave Asprey.
Biohackers, wellness seekers and consumers will connect with today’s visionaries, disruptors and innovators who are pushing the boundaries for human advancement, performance and longevity. The captivating keynote speakers and featured presenters will include Asprey, Dr. Gabrielle Lyon, a board-certified family physician, Teal Swan, author and spiritual thought leader, Hal Elrod, bestselling author and motivational speaker, and Dr. Alberto Villoldo, medical anthropologist and shaman.
Attendees looking to “Live Beyond 180” will also experience over 100 biohacking brands and activations showcasing cutting-edge technologies and latest innovations that empower individuals to become the CEOs of their own health, including returning title sponsor, STEMREGEN, the trailblazer in stem cell science-backed supplements.
“For over a decade, this Conference has reigned supreme as the premiere health, longevity and well-being event,” says Asprey. “2025 will be an epic adventure with a curated lineup of the most brilliant minds, top experts, and trailblazing innovators to help you master your biology and unleash your full potential, for 180 years and beyond.”
The Biohacking Conference just wrapped up its tenth year, hosted for the first time in Dallas, TX, with the biggest event to date with over 3,000 attendees.
Ticket Prices:
2025 Biohacking Conference Location:
Fairmont Austin
101 Red River Street
Austin, TX
For more information visit BiohackingConference.com
MEDIA CONTACT:
Stanton & Company
Ashley Beenen
ashley@stanton-company.com
SOURCE Biohacking Conference
SEATTLE, Dec. 06, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage…
– Data support initiation of a combination cohort in the ongoing Phase 1 clinical trial…
SPRING, Texas, Dec. 06, 2025 (GLOBE NEWSWIRE) -- Io Therapeutics, Inc., a privately held pharmaceutical…
Ficerafusp alfa 750mg QW in combination with pembrolizumab demonstrates consistent overall response rate and safety…
TUS+VEN+AZA triplet frontline therapy demonstrates high rates of efficacy and MRD-negative remissions in newly diagnosed…
Demonstrated meaningful overall anemia responses across all patient subgroups, regardless of baseline transfusion status Anemia response…